Swipe om te navigeren naar een ander artikel
To measure quality of life (QOL) and utilities for prostate cancer (PC) patients and determine their predictors.
A population-based, community-dwelling, geographically diverse sample of long-term PC survivors in Ontario, Canada, was identified from the Ontario Cancer Registry and contacted through their referring physician. Consenting patients completed questionnaires by mail: Health Utilities Index (HUI 2/3), Patient Oriented Prostate Utility Scale PORPUS-U (utility), PORPUS-P (health profile), Functional Assessment of Cancer Therapy-Prostate (FACT-P), and Prostate Cancer Index (PCI). Clinical data were obtained from chart reviews. Regression models determined the effects of a series of variables on QOL and utility.
We received questionnaires and reviewed charts for 585 patients (mean age 72.6, 2–13 years postdiagnosis). Mean utility scores were as follows: PORPUS-U = 0.92, HUI2 = 0.85, and HUI3 = 0.78. Mean health profile scores were as follows: PORPUS-P = 71.7, PCI sexual, urinary, and bowel function = 23.7, 79.1, and 84.6, respectively (0 = worst, 100 = best), and FACT-P = 125.1 (0 = worst, 156 = best). In multiple regression analyses, comorbidity and PCI urinary, sexual, and bowel function were significant predictors of other QOL measures. With all variables, 32–50 % of the variance in utilities was explained.
Many variables affect global QOL of PC survivors; only prostate symptoms and comorbidity have independent effects. Our model allows estimation of the effects of multiple factors on utilities. These utilities for long-term outcomes of PC and its treatment are valuable for decision/cost-effectiveness models of PC treatment.
Log in om toegang te krijgen
Met onderstaand(e) abonnement(en) heeft u direct toegang:
Lin, K., Croswell, J. M., Koenig, H., Lam, C., & Maltz, A. (2011) Prostate-specific antigen-based screening for prostate cancer: An evidence update for the U.S. preventive services task force. AHRQ publication no. 12-05160-EF-1, Oct 2011. Evidence synthesis number 90 (Screening for prostate cancer, topic page. U.S. Preventive Services Task Force. http://www.uspreventiveservicestaskforce.org/uspstf/uspsprca.htm).
Euroqol Group. (1990). A new facility for the measurement of health related quality of life. Health Policy, 16, 199–208. CrossRef
Drummond, M. F., Sculpher, M. J., Torrance, G. W., O’Brien, B. J., & Stoddart, G. L. (2005). Chapter 6: Cost-utility analysis. In Methods for the economic evaluation of health care programmes. New York: Oxford University Press.
Hayes, J. H., Ollendorf, D. A., Pearson, S. D., Barry, M. J., Kantoff, P. W., Stewart, S. T., et al. (2010). Active surveillance compared with initial treatment for men with low-risk prostate cancer. A decision analysis. The Journal of the American Medical Association, 304, 2373–2380. CrossRef
Krahn, M. D., Bremner, K. E., Tomlinson, G., & Naglie, G. (2009). Utility and health-related quality of life in prostate cancer patients 12 months after radical prostatectomy or radiation therapy. Prostate Cancer and Prostatic Diseases, 12, 361–368. CrossRef
Ferlay, J., Shin, H.-R., Bray, F., Forman, D., Mathers, C., & Parkin, D. M. (2010). Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. International Journal of Cancer, 127, 2893–2917. CrossRef
Cabrol, M. P. R: A language and environment for statistical computing. R Foundation for Statistical Computing Vienna, Austria.
SAS Inc. SAS 9.1.3 for Windows. Cary, NC, USA.
Van Buuren, S., & Oudshoorn, CGM. (1999) Flexible multivariate imputation by MICE. Leiden: TNO preventie en Gezondheid, TNO/VGZ/PG 99054.
Crook, J., Borg, J., Evans, A., Toi, A., Saibishkumar, E. P., Fung, S., et al. (2011). 10-year experience with I-125 prostate brachytherapy at the Princess Margaret Hospital: Results for 1,100 patients. International Journal of Radiation Oncology Biology Physics, 80, 1323–1329. CrossRef
Crook, J., Lukka, H., Klotz, L., Bestic, N., Johnston, M., & The Genitourinary Cancer Disease Site Group of the Cancer Care Ontario Practice Guidelines Initiative. (2001). Systematic overview of the evidence for brachytherapy in clinically localized prostate cancer. Canadian Medical Association Journal, 164, 975–981. PubMed
Kopec, J. A., Williams, J. I., To, T., & Austin, P. C. (2000). Measuring population health: Correlates of the health utilities index among English and French Canadians. Canadian Journal of Public Health, 91, 465–470. PubMed
Statistics Canada. (2006) Census of population. Statistics Canada catalogue no. 97-560-XCB2006008 (Ontario, Code35) Date modified: 2011-04-07.
Statistics Canada. (2006). Catalogue number 97-563-XCB2006005.2006 census.
Willis, D. L., Gonzalgo, M. L., Brotzman, M., Feng, Z., Trock, B., & Su, L.-M. (2011). Comparison of outcomes between pure laparoscopic vs robot-assisted laparoscopic radical prostatectomy: A study of comparative effectiveness based upon validated quality of life outcomes. BJU International, 109, 898–905. PubMedCrossRef
Al-Mamgani, A., Heemsbergen, W. D., Peeters, S. T., & Lebesque, J. V. (2009). Role of intensity-modulated radiotherapy in reducing toxicity in dose escalation for localized prostate cancer. International Journal of Radiation Oncology Biology Physics, 73, 685–691. CrossRef
Zelefsky, M. J., Levin, E. J., Hunt, M., Yamada, Y., Shippy, A. M., Jackson, A., et al. (2008). Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. International Journal of Radiation Oncology Biology Physics, 70, 1124–1129. CrossRef
- A reference set of health utilities for long-term survivors of prostate cancer: population-based data from Ontario, Canada
Murray D. Krahn
Karen E. Bremner
Shabbir M. H. Alibhai
- Springer Netherlands